Today: 20 May 2026
Tesla stock slides on Europe sales slump as BYD gains; traders eye Jan. 28 earnings

Tesla stock slides on Europe sales slump as BYD gains; traders eye Jan. 28 earnings

New York, January 6, 2026, 10:10 (EST) — Regular session

Tesla (TSLA) shares fell 3.2% to $437.13 in morning trade on Tuesday after German road traffic agency KBA said the automaker sold 2,032 cars in Germany in December, down 48% from a year earlier. KBA said Tesla’s 2025 sales in Germany fell 48.4% to 19,390 vehicles; the stock has traded between $437.05 and $452.25 after ending Monday at $451.67.

Tesla’s UK registrations — a proxy for sales — slid more than 29% in December to 6,323 vehicles, as Chinese rival BYD’s registrations jumped nearly five-fold to 5,194, industry data showed. Tesla remained Britain’s top-selling EV brand for the month, but the drop echoed other European markets where Tesla has been hit by competition, an ageing lineup and backlash linked to CEO Elon Musk’s political stance; Tesla also ceded its crown as the world’s top EV maker to BYD after reporting a second straight annual decline in sales. Society of Motor Manufacturers and Traders chief executive Mike Hawes said “the pace is still too slow and the cost to industry too high,” while Auto Express’ Steve Walker said Chinese entrants are “creating fierce competition that will continue to force prices down.” Reuters

The pressure on Tesla’s core car business lands as investors look for the next growth engine, with autonomous driving and artificial intelligence taking center stage at CES 2026 in Las Vegas this week. “This year you will see more and more focus on AI and autonomous,” said PwC’s U.S. automotive industry leader C.J. Finn, as automakers dial back EV launches amid policy shifts and cost concerns. Reuters cited Tesla’s launch of a small robotaxi service with safety monitors in Austin last year, alongside faster expansion by Alphabet’s Waymo, as reigniting interest in the sector. Reuters

Tesla had climbed 3.1% on Monday, snapping a seven-session losing streak, as Wall Street rallied. The next test for rate-sensitive growth stocks comes with Friday’s U.S. nonfarm payrolls report — the government’s monthly jobs report — while markets were pricing in about 60 basis points (0.60 percentage point) of Federal Reserve easing in 2026, Reuters reported.

But monthly registration data can swing with delivery timing and fleet orders, making the signal noisy. A prolonged slide in Europe would likely rekindle pressure for incentives and price cuts, risking a fresh squeeze on margins.

Stock Market Today

  • Stock Market Today May 20: Nasdaq Rises 1.5% on Renewed Risk Appetite
    May 20, 2026, 5:43 PM EDT. The S&P 500 gained 1.08% to 7,432.97, Nasdaq rose 1.54% to 26,270.36, and Dow advanced 1.31% to 50,009.34 amid falling oil prices and easing Treasury yields. AI hardware stocks like AMD and Super Micro Computer led gains, with Nvidia up 1.3% before its earnings report. Software names Salesforce and CrowdStrike also recovered. Hasbro declined nearly 9% despite beating earnings forecasts due to cautious guidance. Investor optimism reflects hopes for an end to the U.S.-Iran conflict, lowering West Texas Intermediate crude by 5% to $99 a barrel. Nvidia's earnings beat was met with muted reaction as investors awaited stronger sales forecasts. The Motley Fool highlighted other top stock picks, noting Nvidia and Netflix's historic outperformance over the S&P 500.

Latest articles

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

MicroAlgo Shares Surge 40% as Quantum Release Drives MLGO Spike

20 May 2026
MicroAlgo shares surged 39.95% to $5.36 after the company announced a quantum image-processing algorithm, with volume reaching 9.74 million shares versus a 447,270 average. The stock hit $6.87 intraday before slipping to $5.22 after hours. No customer deals, revenue targets, or product launch dates were disclosed. Market cap stood near $66.7 million at the close.
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT

20 May 2026
Immunovant shares jumped 35.3% to $35.56 after reporting 16-week data showing its drug IMVT-1402 produced ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% in difficult-to-treat rheumatoid arthritis. Roivant Sciences, its majority owner, rose 14.9%. No new safety signals were reported. The trial enrolled 170 patients, most of whom had failed two prior advanced therapies.
FuelCell Energy surges as AI-fueled rally hits again, analysts wary

FuelCell Energy surges as AI-fueled rally hits again, analysts wary

20 May 2026
FuelCell Energy shares surged 16.5% to $20.22 Wednesday, rebounding after a two-day selloff. The move tracked a 1.5% gain in the Nasdaq Composite and renewed interest in companies supplying power to AI data centers. FuelCell reported a $26.1 million quarterly loss and a declining backlog, despite higher revenue and new data-center proposals. Peers traded mixed, with Bloom Energy up and Plug Power down.
Amazon stock edges up on AWS self-driving push as lawsuit keeps AMZN in focus
Previous Story

Amazon stock edges up on AWS self-driving push as lawsuit keeps AMZN in focus

Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure
Next Story

Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure

Go toTop